- Home
- EVAX vs IBIO Comparison
EVAX vs IBIO Comparison
Compare EVAX & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- IBIO
- Stock Information
- Founded
- EVAX 2008
- IBIO 2008
- Country
- EVAX Denmark
- IBIO United States
- Employees
- EVAX N/A
- IBIO N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- IBIO Health Care
- Exchange
- EVAX Nasdaq
- IBIO Nasdaq
- Market Cap
- EVAX 17.8M
- IBIO 16.4M
- IPO Year
- EVAX 2021
- IBIO N/A
- Fundamental
- Price
- EVAX $5.75
- IBIO $1.60
- Analyst Decision
- EVAX Strong Buy
- IBIO Strong Buy
- Analyst Count
- EVAX 3
- IBIO 4
- Target Price
- EVAX $12.33
- IBIO $4.50
- AVG Volume (30 Days)
- EVAX 792.1K
- IBIO 8.0M
- Earning Date
- EVAX 11-06-2025
- IBIO 10-31-2025
- Dividend Yield
- EVAX N/A
- IBIO N/A
- EPS Growth
- EVAX N/A
- IBIO N/A
- EPS
- EVAX N/A
- IBIO N/A
- Revenue
- EVAX $3,176,000.00
- IBIO $400,000.00
- Revenue This Year
- EVAX $129.34
- IBIO N/A
- Revenue Next Year
- EVAX N/A
- IBIO N/A
- P/E Ratio
- EVAX N/A
- IBIO N/A
- Revenue Growth
- EVAX 1042.45
- IBIO 77.78
- 52 Week Low
- EVAX $1.20
- IBIO $0.56
- 52 Week High
- EVAX $14.38
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- EVAX 49.57
- IBIO 78.52
- Support Level
- EVAX $5.60
- IBIO $1.02
- Resistance Level
- EVAX $6.82
- IBIO $1.78
- Average True Range (ATR)
- EVAX 1.27
- IBIO 0.23
- MACD
- EVAX -0.28
- IBIO 0.06
- Stochastic Oscillator
- EVAX 6.71
- IBIO 81.82
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.